{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:38:28Z","timestamp":1760852308943},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.clinthera.2007.06.009","type":"journal-article","created":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T07:38:50Z","timestamp":1186645130000},"page":"1116-1127","source":"Crossref","is-referenced-by-count":7,"title":["Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: The role of comparative studies and implications for future studies"],"prefix":"10.1016","volume":"29","author":[{"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao L.C.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel Diaz","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.06.009_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2007.06.009_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2007.06.009_bib3","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib4","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2007.06.009_bib5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2007.06.009_bib6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2007.06.009_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.06.009_bib8","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2007.06.009_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2007.06.009_bib11","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"key":"10.1016\/j.clinthera.2007.06.009_bib12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.06.009_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00198-003-1571-4","article-title":"Alendronate in the prevention of osteoporosis: 7-Year follow-up","volume":"15","author":"Sambrook","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2007.06.009_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2007.06.009_bib15","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study","volume":"24","author":"Simon","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2007.06.009_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","article-title":"Patients with osteoporosis prefer once weekly to once daily dosing with alendronate","volume":"48","author":"Kendler","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.clinthera.2007.06.009_bib17","first-page":"31","article-title":"Bisphosphonate dosing preferences in women with postmenopausal osteoporosis: A study","volume":"30","author":"Simon","year":"2005","journal-title":"Female Patient"},{"key":"10.1016\/j.clinthera.2007.06.009_bib18","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","article-title":"Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO)","volume":"21","author":"Emkey","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2007.06.009_bib19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","article-title":"Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis","volume":"21","author":"Cramer","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2007.06.009_bib20","first-page":"856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women","volume":"80","author":"Recker","year":"2005"},{"key":"10.1016\/j.clinthera.2007.06.009_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2006.01.002","article-title":"Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis","volume":"28","author":"Penning-van Beest","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2007.06.009_bib22","first-page":"807","article-title":"Adherence to bisphosphonates (BPs) is associated with reduced fracture risk in women with postmenopausal osteoporosis (PMO)","volume":"12","author":"Siris","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.clinthera.2007.06.009_bib25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-133-6-200009190-00017","article-title":"Are placebo-controlled clinical trials ethical or needed when alternative treatment exists [published correction appears in Ann Intern Med. 2000;133:754]","volume":"133","author":"Simon","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2007.06.009_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues","volume":"133","author":"Temple","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2007.06.009_bib27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-133-6-200009190-00015","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases","volume":"133","author":"Ellenberg","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2007.06.009_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s198-002-8331-3","article-title":"The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis","volume":"13","author":"Delmas","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2007.06.009_bib29","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1359\/jbmr.2003.18.6.1105","article-title":"Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?","volume":"18","author":"Brody","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1359\/jbmr.2003.18.6.1117","article-title":"Ethical issues in the design of osteoporosis clinical trials: The state of the question","volume":"18","author":"Heaney","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib31","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1359\/jbmr.2003.18.6.1121","article-title":"Scientific and ethical issues in the use of placebo and active controls in clinical trials","volume":"18","author":"Ellenberg","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib32","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1359\/jbmr.2003.18.6.1129","article-title":"Study designs in osteoporosis","volume":"18","author":"Temple","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib33","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1359\/jbmr.2003.18.6.1142","article-title":"Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective","volume":"18","author":"Rosenblatt","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1359\/jbmr.2003.18.6.1160","article-title":"Osteoporosis panel summary","volume":"18","author":"Capron","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-005-1984-3","article-title":"Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men","volume":"17","author":"Reginster","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2007.06.009_bib36","first-page":"1905","article-title":"ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials","volume":"18","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2007.06.009_bib38","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jama.282.14.1371","article-title":"Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect","volume":"282","author":"McAlister","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2007.06.009_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/bmj.313.7048.36","article-title":"Trials to assess equivalence: The importance of rigorous methods [published correction appears in BMJ. 1996;313:550]","volume":"313","author":"Jones","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2007.06.009_bib41","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1359\/jbmr.2003.18.6.1133","article-title":"Study design in osteoporosis: A European perspective","volume":"18","author":"Kanis","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.clinthera.2006.02.004","article-title":"Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6\u201312 months) safety of acetaminophen in adult patients with osteoarthritis","volume":"28","author":"Temple","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2007.06.009_bib43","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2007.06.009_bib44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s001980200052","article-title":"Uncertain future of trials in osteoporosis","volume":"13","author":"Kanis","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2007.06.009_bib45","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1359\/jbmr.2003.18.6.1110","article-title":"Ethical issues in clinical research on fracture prevention in patients with osteoporosis","volume":"18","author":"Fost","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib46","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2007.06.009_bib47","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turn-over and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib48","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib49","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turn-over and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib50","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.87.4.1586","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2007.06.009_bib51","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jc.85.1.231","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2007.06.009_bib52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079905X41390","article-title":"How useful are measures of BMD and bone turnover?","volume":"21","author":"Miller","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2007.06.009_bib53","first-page":"379","article-title":"The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy","volume":"80","author":"Epstein","year":"2005"},{"key":"10.1016\/j.clinthera.2007.06.009_bib54","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial [published correction appears in JAMA. 1999;282:2124]","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2007.06.009_bib55","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.06.009_bib56","series-title":"Office of the Surgeon General. Bone health and osteoporosis: A report of the Surgeon General","author":"US Dept of Health and Human Services","year":"2004"},{"key":"10.1016\/j.clinthera.2007.06.009_bib57","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.06.009_bib58","first-page":"S398","article-title":"Rationale and design of the MOTION study (Monthly Oral Therapy with lbandronate for Osteoporosis iNtervention)","volume":"20","author":"Cosman","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib59","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2007.06.009_bib60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.06.009_bib62","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1210\/jc.2005-2602","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years","volume":"91","author":"Bonnick","year":"2006","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T03:26:31Z","timestamp":1546658791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807001683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0149291807001683"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.06.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}